Search for: "BRISTOL MYERS SQUIBB" Results 621 - 640 of 866
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Apr 2011, 6:01 pm by Thom Lambert
  to join Bristol Myers Squibb and GlaxoSmithKline in their efforts to prevent the illegal production of patented AIDS drugs in Africa? [read post]
30 Aug 2011, 2:00 am by Stefanie Levine
US 6,475,521entitled BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD and owned by Bristol-Myers Squibb Co. [read post]
30 Aug 2011, 2:00 am by Stefanie Levine
US 6,475,521entitled BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD and owned by Bristol-Myers Squibb Co. [read post]
12 Jun 2014, 10:41 am by Jason Rantanen
Bristol-Myers Squibb Company v. [read post]
1 Oct 2007, 1:08 am
Bristol-Myers Squibb to Pay $515M to Settle Probes of Drug Marketing The Associated Press Bristol-Myers Squibb Co. and a former subsidiary have agreed to pay more than $515 million to settle federal and state investigations into their drug marketing and pricing practices. [read post]
8 Apr 2016, 9:14 am by Lawrence B. Ebert
(“Merial”) and Bristol-Myers Squibb(“BMS”) (together, “appellees”). [read post]
11 Jan 2013, 6:27 pm by Prashant Reddy
The patents for the remaining two drugs – Ixabepilone and Dastinib are owned by Bristol Myers Squibbs (BMS). [read post]
21 Jan 2015, 3:02 pm
Its corporate talking heads (Bristol-Myers Squibb and Pfizer) said such spending helps ensure that providers understand its appropriate use, and how important it is “to have a speaker program that adequately provides robust education to these physicians. [read post]
29 Jul 2013, 2:24 am
 Unfortunately,without any thumbs, he was unable to forwardthem to the true recipient, Bristol-Myers Squibb When the parties engaged in correspondence, Teva refused to divulge its launch plans as it considered these plans confidential. [read post]
29 Nov 2013, 3:43 am
Bristol-Myers Squibb Co., No. 13-1405, 2013 U.S. [read post]
6 Feb 2019, 6:12 am
Regulation of medicinal productsGuestKat Frantzeska Papadopoulou explored the issue of the regulation of orphan drugs in the context of the General Court decision on an action brought by Bristol-Myers Squibb Pharma (BMS) against the Commission and the European Medicines Agency (EMA) in the case T‑329/16: Orphan Drugs, a successful regulation after all? [read post]
10 Apr 2015, 2:00 am
We reported to you last August on Bristol-Myers Squibb Co. v. [read post]